Processing of positive newborn screening results: a qualitative exploration of current practice in England by Chudleigh, J. H. et al.
              
City, University of London Institutional Repository
Citation: Chudleigh, J. H. ORCID: 0000-0002-7334-8708, Chinnery, H., Holder, P., 
Carling, R. S., Southern, K., Olander, E. K. ORCID: 0000-0001-7792-9895, Moody, L., 
Morris, S., Ulph, F., Bryon, M. and Simpson, A. (2020). Processing of positive newborn 
screening results: a qualitative exploration of current practice in England. BMJ Open, 10(12), 
e044755.. doi: 10.1136/bmjopen-2020-044755 
This is the published version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/25461/
Link to published version: http://dx.doi.org/10.1136/bmjopen-2020-044755
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
1Chudleigh J, et al. BMJ Open 2020;10:e044755. doi:10.1136/bmjopen-2020-044755
Open access 
Processing of positive newborn 
screening results: a qualitative 
exploration of current practice 
in England
Jane Chudleigh   ,1 Holly Chinnery,2 Pru Holder,1 Rachel S Carling,3 
Kevin Southern,4 Ellinor Olander,1 Louise Moody,5 Stephen Morris   ,6 
Fiona Ulph,7 Mandy Bryon,8 Alan Simpson9
To cite: Chudleigh J, 
Chinnery H, Holder P, et al.  
Processing of positive newborn 
screening results: a qualitative 
exploration of current practice 
in England. BMJ Open 
2020;10:e044755. doi:10.1136/
bmjopen-2020-044755
 ► Prepublication history and 
additional material for this paper 
is available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 044755).
Received 11 September 2020
Revised 04 November 2020
Accepted 20 November 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Jane Chudleigh;  
 j. chudleigh@ city. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objective To explore current communication practices 
for positive newborn screening results from the newborn 
bloodspot screening (NBS) laboratory to clinicians to 
highlight differences, understand how the pathways are 
implemented in practice, identify barriers and facilitators 
and make recommendations for future practice and 
research.
Design A qualitative exploratory design was employed 
using semi- structured interviews.
Setting Thirteen NBS laboratories in England.
Participants Seventy- one clinicians; 22 NBS laboratory 
staff across 13 laboratories and 49 members of relevant 
clinical teams were interviewed.
Results Assurance of quality and consistency was a 
priority for all NBS laboratories. Findings indicated variation 
in approaches to communicating positive NBS results from 
laboratories to clinical teams. This was particularly evident 
for congenital hypothyroidism and was largely influenced 
by local arrangements, resources and the fact individual 
laboratories had detailed standard operating procedures 
for how they work. Obtaining feedback from clinical teams 
to the laboratory after the child had been seen could 
be challenging and time- consuming for those involved. 
Pathways for communicating carrier results for cystic 
fibrosis and sickle cell disease could be ambiguous and 
inconsistent which in turn could hamper the laboratories 
efforts to obtain timely feedback regarding whether or 
not the result had been communicated to the family. 
Communication pathways for positive NBS results between 
laboratories and clinical teams could therefore be time- 
consuming and resource- intensive.
Conclusion The importance placed on ensuring positive 
NBS results were communicated effectively and in a 
timely fashion from the laboratory to the clinical team was 
evident from all participants. However, variation existed in 
terms of the processes used to report positive NBS results 
to clinical teams and the people involved. Variant practice 
identified may reflect local needs, but more often reflected 
local resources and a more consistent ‘best practice’ 
approach is required, not just in the UK but perhaps 
globally.
Trial registration number ISRCTN15330120.
INTRODUCTION
In the UK, newborn bloodspot screening 
(NBS) comprises a heel prick blood sample 
taken via a NBS card between days 5 to 8 of 
life to identify pre- symptomatic babies that 
are affected by genetic or congenital condi-
tions.1 It is known that early diagnosis leads 
to better health outcomes for the child.1 2 In 
the UK, since January 2015, NBS covers nine 
conditions (table 1).
Each year, around 10 000 babies born in 
the UK have a positive NBS result. These 
positive NBS results include both babies who 
will eventually be diagnosed as being affected 
by one of the nine life- changing conditions 
currently screened for3 4 (n=approximately 
1500), those who will later be confirmed as 
gene carriers for sickle cell disorder (SCD) 
or cystic fibrosis (CF) but unaffected by the 
disease and babies who screen positive but 
for whom screened disease is ruled out (false- 
positive results).
Communicating presumptive positive NBS results
NBS laboratory guides are available for 
each of the conditions included in the NBS 
Strengths and limitations of this study
 ► This is the first known study that has explored com-
munication pathways for positive newborn blood-
spot screening (NBS) results from the laboratory to 
clinical teams.
 ► Participants represented the 13 NBS laboratories in 
England involved in managing the nine conditions 
currently included in the NBS programme increasing 
the transferability of the findings.
 ► The study design, data collection and analysis were 
influenced by members of the patient and public 
involvement advisory group and relevant charities.
 ► The researchers are experienced in this field which 
may have biassed data collection and analysis.
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Programme in the UK.5–9 Positive NBS results are referred 
to as being ‘presumptive positive’ (PP) results. That is, 
the result is presumed to indicate a positive result until 
further diagnostic testing is undertaken to either confirm 
or rule out the condition being screened for. Within each 
condition, there is specific information on how PP cases 
should be reported and communicated. While some 
aspects of the pathways are similar, some are very different 
such as the time frame for the first clinic appointment. 
Table 2 summarises the different pathways as established 
in the guides, for each of the screened conditions.
Communicating positive NBS results is not an event but 
a process that starts from the moment the result is iden-
tified by the NBS laboratory as being above the agreed 
analytical ‘cut- off’ and ends when the parents are given 
the definitive diagnosis for their child.10 Most literature 
to date has focussed on how positive NBS results are 
communicated to families via appropriate clinicians.11–16 
These studies have highlighted that despite guidance, 
this occurs in a range of ways which are not currently well- 
defined. In addition, poor, or inappropriate, strategies 
for communication of positive NBS result to families can 
influence parental outcomes in the short term11 13 16–19 
but may also have a longer term impact on children and 
families.20
The NBS laboratory guides5–9 provide detailed expla-
nations regarding the analytical aspects of NBS, quality 
assurance, clinical referral and follow- up and reporting 
and data collection for each of the screened conditions. 
However, no literature has explored how the process of 
communication from the laboratory to clinical teams is 
implemented in practice and how this might influence 
communication with families.
The purpose of the current study was to explore 
current communication practices for positive newborn 
screening results from the NBS laboratory to clinicians to 
highlight differences, understand how the pathways are 
implemented in practice, identify barriers and facilitators 
and make recommendations for future practice. Health 
professionals’ experiences of communicating positive 
NBS results to families have been reported elsewhere.10
METHODS
A qualitative exploratory design was utilised using semi- 
structured telephone interviews with laboratory staff 
employed in the 13 NBS laboratories in England and 
members of relevant clinical teams notified of positive 
NBS results from the respective NBS laboratories. This 
study is part of an ongoing programme of work21 and 
was approved by the London Stanmore ethics committee 
(17/LO/2102).
Patient and public involvement
Patient and public involvement (PPI) was instrumental 
in the design and conduct of this study. Eight parents 
of babies who had received a positive NBS screening 
result for one of the nine screened conditions formed 
a PPI advisory group who met prior to, during and 
following data collection. Their suggestions were incor-
porated into the study design, the data collection tools 
and the data analysis and presentation. The PPI group 
were presented with data from the annual reports of the 
NBS Programmes and made suggestions as to which sites 
should be used in later phases of the study design. The 
PPI group also suggested clarifying that positive NBS 
results indicated an ‘abnormal’ result while negative NBS 
results indicated a ‘normal’ result during data collection, 
as they had found this confusing when they received their 
child’s NBS result. Initial findings of were presented to 
member of the PPI group during regular 6- month meet-
ings and drafts of manuscripts were also shared with PPI 
members to ensure these were presented in a readable 
format. In addition, we obtained the views of representa-
tives from charities for the screened conditions including 
Metabolic Support UK, the British Thyroid Foundation, 
the CF Trust and the Sickle Cell Society.
Setting
In England, there are 13 Newborn Screening laborato-
ries that process the results for the nine conditions that 
are currently included in the NBS Programmes, these 
comprised the study sites.
Inclusion and exclusion criteria
Staff employed in NBS laboratories and involved in 
the processing of positive NBS results and members of 
relevant clinical teams who had received a positive NBS 
from NBS laboratories in the previous 6 months were 
included. Staff who had not been involved in processing 
or receiving positive NBS results in the last 6 months or 
who had personal experience of receiving a positive NBS 
result were excluded.
Recruitment and sampling
A two- stage sampling approach was employed where 
participants were first sampled purposively based on their 
experience with the phenomena of interest, followed 
by a second stage of snowball sampling where the first 
participants suggested others. Directors of all 13 NBS 
laboratories in England were invited to participate. These 
were identified through the UK Newborn Screening 
Table 1 Conditions included in the newborn bloodspot 
screening programme
Name of condition Abbreviation




Glutaric aciduria type 1 GA1
Medium chain acyl CoA 
dehydrogenase deficiency
MCADD
Maple syrup urine disease MSUD
Isovaleric aciduria IVA
Congenital hypothyroidism CHT
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Laboratories Network (http://www. newbornscreening. 
org/ site/ laboratory- directory. asp) and were contacted 
via email by a member of the research team. Directors 
of newborn screening laboratories were invited to be the 
local principal investigator for their study site and were 
asked to provide names and contact details of staff within 
the laboratory who met the inclusion criteria for the 
study. These staff members were contacted via email and 
invited to participate.
Representative members of local clinical teams 
(medical consultants; general paediatricians; nurse 
specialists; health visitors; specialist screening nurses and 
genetic counsellors) were identified through individual 
trust websites and contacted via email to be invited to 
participate. Those who agreed to participate were also 
asked to identify other members of their team who they 
thought should be interviewed to provide further infor-
mation about the NBS process. These additional poten-
tial participants were also contacted by email and invited 
to participate. Written informed consent was obtained 
from all participants.
Data collection
Semi- structured telephone interviews comprising closed 
and open- ended questions were conducted by JC between 
June 2018 and February 2019 to identify the approaches 
used to communicate positive NBS results from NBS labo-
ratories to health professionals (online supplemental file 
1). Data were collected on: the mode of communication 
strategy (face- to- face; letter; telephone; and e- mail); the 
resources involved in each communication strategy; who 
provides the information and their role; and location 
(co- located or alternative site) of relevant services for 
each condition.
Data analysis
The purpose of data analysis was to describe and identify 
approaches currently used to communicate positive NBS 
results from NBS laboratories to health professionals. 
Qualitative data from open- ended questions were anal-
ysed using thematic analysis22 with an inductive approach. 
Data from laboratory staff and clinical staff were analysed 
separately. Seven interview transcripts from laboratory 
staff were coded by two members of the research team (JC 
and HC) to aid in coding comparisons and inform and 
align code development.23 A code book was developed 
based on these jointly coded transcripts. A further seven 
laboratory transcripts were then coded separately by the 
same two members of the research team using the code 
book. These separately coded transcripts were compared, 
a similar process was followed for the transcripts for clin-
ical staff. Following this, the same two members of the 
research team coded the remainder of the laboratory 
and clinical staff transcripts using the relevant code 
books. This was an ongoing, iterative process; new codes 
were developed and the definition of codes refined as 
analysis progressed.24 Once this initial coding had been 
completed, these codes were then collapsed into themes. 
Communication pathways for each condition for each of 
the 13 NBS laboratories (unit of analysis) were also devel-
oped (online supplemental file 2).
Positionality and reflexivity
Members of the study team (JC, LM, FU, MB and KWS) 
have been involved in or continue to undertake a variety 
of roles and activities associated with the NBS Programme 
in the UK. It is acknowledged that this could have led 
to potential bias during data collection and analysis. 
However, this was balanced by other members of the 
research team who had previously had minimal involve-
ment in NBS (HC, EKO, AS, SM and PH). Data collec-
tion was undertaken by JC and data analysis was mainly 
undertaken by JC and HC who fall within both camps. 
Neither JC nor HC were employed in the organisations 
where data collection was undertaken.
RESULTS
In total, 71 interviews were conducted: 22 with NBS labo-
ratory staff across 13 laboratories and 49 with members of 
clinical teams. Four eligible participants declined to be 
interviewed. Demographics of participants can be seen in 
table 3.
Themes
Five themes were identified from the data: the importance 
of the result to the child and family; different referral 
Table 3 Demographics of participants
NBS laboratory staff
Profession
Number of staff 
interviewed
Director of NBS laboratory 9
Consultant biochemist/haematologist 2
Senior/ clinical scientist 11
Length of service Median 12.0 years Range 1.0 to 22.0 
years
Length of interview Median 30.8 min Range 13.3 to 
45.1 mins
Clinical teams
Profession Number of staff 
interviewed
Medical consultant 21
Clinical nurse specialist 21
Screening specialist nurse/midwife 5
Service coordinator 1
Paediatric dietician 1
Length of service Median 11.0 years Range 1.5 to 23.0 
years
Length of interview Median 33.4 min Range 10.4 to 
54.6 mins
NBS, newborn blodspot screening.
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approaches for different conditions; no unified process 
to provide feedback to laboratories; providing carrier 
results; inconsistency and ambiguity and resource use 
and responsibilities. These are explored in detail below 
and supported by illustrative quotations from interview 
data.
The importance of the result to the child and family
Assurance of quality and consistency was a clear priority 
for all NBS laboratories. This applied to all aspects of 
analysis, including quality checks of the NBS card, data 
entry, first line and, if required, second line testing, and 
timeliness of reporting. There was also a clear apprecia-
tion of the significance of the results for families.
…everybody is aware there is a baby at the end of this, 
there’s a family at the end of this and everybody wants 
to do the best by that family. So, I think because of 
that everybody pulls together really well and makes 
sure, even if it’s bad timing, which it usually is, ev-
erybody still pulls together to make sure it happens. 
Site 13
In addition, laboratory staff clearly appreciated the 
urgency of communicating positive NBS results to clini-
cians particularly for the inherited metabolic diseases 
(IMDs), including medium chain acyl CoA dehydroge-
nase deficiency (MCADD), maple syrup urine disease 
(MSUD), phenylketonuria (PKU), isovaleric aciduria 
(IVA), homocystinuria (HCU) and glutaric aciduria type 
1 (GA1).
Any of the metabolic conditions, if we see a raised 
result for first time, we will repeat that immediately. 
So, rather than it going through the system and being 
repeated, and us only getting the second result the 
next day, we’d repeat it immediately, so we repeat it 
effectively offline, and then if it turns out to be posi-
tive, we would make the referral straight away. Site 8.
Different referral approaches for different conditions
Even though national guidelines are available from 
Public Health England for referring positive NBS results 
from the laboratory to the relevant clinicians, 10 out of 
13 of the laboratories created their own templates for this 
purpose following further development and improve-
ment by staff:
… we have a proforma that we send …when we get 
the results. I know there’s a national one which we’ve 
looked at but we think our own one probably ticks 
more boxes. From our point of view, it seems to work 
for us better Site 7
When a positive NBS result occurs, referrals are made 
to a range of different clinicians including condition 
specific consultants, their secretaries, condition specific 
specialist nurses, specialist screening nurses or screening 
co- ordinators. The referral process was often based on 
local arrangements, resources and the fact individual 
laboratories had detailed standard operating procedures 
for how they work. These could be quite complex with 
variation for each condition and often the need to cover 
large geographical areas. However, usually, these were 
well understood and implemented.
…we’ve got SOPs (standard operating procedures) 
that define where we need to call for whichever result 
in whichever place…for our congenital hypothyroid-
ism, we have named consultants at (Hospital E). We 
have a name for (Hospital F) and (Hospitals G, H, I 
and J) where we’ll just report to an on- call paediatri-
cian, So, PKU only if they’re (Hospital J) babies we re-
port to a (Hospital J) paediatrician, or there’s one of 
two (Hospital J) paediatricians. If we can’t get them, 
then it goes to the metabolic team at the (Hospital 
A). Then, MCADD babies if they are (Hospital E) 
or (Hospital J), then we can report them either to 
a (Hospital E) named clinician or the (Hospital J) 
named clinicians. Again, if they’re not available, then 
they’ll go down to the metabolic team at (Hospital 
A) Site 3
Many factors were seen to promote effective commu-
nication between the laboratory and clinical teams. This 
included teams being small which meant everyone within 
the team knew one another and understood each other’s 
roles; the proximity of teams within sites made communi-
cation easier between laboratory staff and relevant clin-
ical teams; and good working relationships among teams 
within the same hospital and across sites.
I think the close relationship between all the differ-
ent professional groups for this part of the country 
works extremely well. Everybody tends to know each 
other personally; it means there are no barriers to dis-
cussion… Now, increasingly, we’re working as close-
ly as we can with (Hospital D) in particular…they’ll 
all cover each other, and the labs work quite closely 
together. We have joint meetings occasionally and to 
some extent, we have a joint strategic vision because 
there are specialist lab things that each one of the 
three of us do. So, we’re trying to develop separate 
areas and compliment rather than compete. Site 9
However, for many laboratories, referral of positive 
NBS results for congenital hypothyroidism (CHT) was 
viewed as more problematic. For all of the other screened 
conditions, dedicated condition specific specialist clin-
ical teams are available to receive the positive NBS result. 
However, while some babies who have a positive NBS result 
for CHT will be seen within specialist endocrine teams, 
CHT is generally viewed as being possible to manage by 
general paediatricians and, therefore, often babies will be 
referred to local paediatric services. This can mean that 
in some instances, there is not a named individual to act 
as a point of contact.
I’m having to go through a switchboard at a different 
hospital to try and find somebody who might not be 
7Chudleigh J, et al. BMJ Open 2020;10:e044755. doi:10.1136/bmjopen-2020-044755
Open access
in that hospital because their clinic’s in another hos-
pital… I would love it if I just had one person to call 
about all my hypothyroidism babies, make my life so 
much easier if I didn’t have to phone different GPs 
and different consultant endocrinologists. Site 10
Despite these challenges, laboratory staff were acutely 
aware of the importance of obtaining this feedback to 
ensure the screening process was complete. Therefore, 
even though it meant that they often had to invest addi-
tional time, laboratory staff would ensure that feedback 
was received so the final outcome (true positive, false 
positive and carrier) could be recorded accurately and 
in a timely manner. Concerns were also raised by labora-
tory staff and members of clinical teams about the equity 
of care particularly in relation to availability of scans 
following a positive NBS result for CHT.
So in terms of equity of care, it would seem that, giv-
en that it’s a national screening programme, people 
should be having the same tests for diagnosis as well. 
Site 4
Conversely, communication of positive CHT NBS 
results to families was seen as being more straightforward 
to manage than some of the other conditions included in 
the NBS programme.
We do far less visits for CHT babies. They’re mainly 
phoned up and told about the results, and then told 
when the appointment is and where …It’s a lot sim-
pler disorder. Site 1
No unified process to provide feedback to laboratories
In the UK, following the referral of a baby with a posi-
tive screening result, NBS laboratories require feedback 
from the relevant clinical team once the baby has been 
seen, assessed and confirmatory testing has been under-
taken. There was no consistent unified national approach 
to providing this feedback, which led to time- consuming 
efforts by the laboratory staff to obtain information. In 
contrast, the responsible clinicians often felt they had a 
clear idea of their duties in this regard.
…if we don’t receive feedback, we have to phone and 
write letter, and that does take quite a bit of time.  
Site 1
This was in contrast to the views of clinicians who were 
responsible for providing the feedback to the NBS labora-
tories who described steps they took to ensure this infor-
mation was fed back to the laboratories. This suggests that 
there may be a mismatch between the information the 
laboratories actually require, the information clinicians 
are providing and who is seen to have ownership of the 
information.
Then, what I will normally do then is email (the NBS 
laboratory) back to say, ‘Yes, the parents will be at-
tending,’ and so on, or, if the parents declined, which 
has never happened, ‘Okay, they’re not coming,’ and 
I would assume they would follow- up. Site 7
The ability of the laboratory to collate and coordinate 
feedback from different sources, after a child had been 
seen, was considered to be particularly challenging and 
time- consuming for CHT. This was often attributed to the 
fact that affected babies were often seen in ‘local’ centres 
rather than tertiary referral centres due to the treatable 
nature of the condition. As a result, clinicians from many 
more localities might be involved in their care. To remedy 
this, some laboratories had sought local solutions to help 
them deal with the difficulties associated with feedback 
for positive NBS results for CHT.
CHT is much more of a problem in this region be-
cause we are not phoning one individual consultant 
in this region…The CHT is, I have to chase around a 
lot more to get that information from other hospitals. 
They are not very forthcoming, often, at providing 
the information so I have to chase around, and often 
I have to get my consultant colleague here, the endo-
crinologist, to help me with that because that can be 
a real challenge. Site 10
This was in contrast to the IMDs where the conditions 
were viewed as being more urgent due to the potential 
life- threatening nature of, particularly, MCADD, MSUD 
and IVA. Also, because affected babies were only seen 
at tertiary centres where often the NBS laboratory staff 
worked closely both physically and personally with IMD 
clinical team members.
…for the IMD conditions, because the consultant 
that sees them is based in the same hospital as me 
(Laboratory Director) and the fact he is my col-
league, we work together to provide the IMD clinical 
service, I do get that information from him. I also can 
see that the diagnostic blood tests have been received 
in our laboratory. So, I know those babies have been 
seen. Site 10
Providing carrier results; inconsistency and ambiguity
Pathways for communicating carrier results to families 
were viewed by some laboratories as ambiguous and incon-
sistent. NBS laboratories expressed concern regarding 
whether parents had been informed of their baby’s SCD 
or CF carrier status and by whom, as this information 
was often difficult for them to ascertain. Carriers are 
healthy children who carry a single faulty gene. The most 
commonly received positive newborn screening result 
is for carrier status for SCD. Communication pathways 
can include a range of health professionals, including 
sickle cell coordinators, sickle cell counsellors, general 
practitioners, and/or health visitors via telephone, letter, 
home visit or during the baby’s health review when they 
are 6 weeks of age. Therefore, although this represents a 
different result scenario (the baby is considered healthy), 
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there is still evidence of inconsistency in terms of the 
pathways used.
… for a child who has who has been found to have 
a carrier status of sickle cell, we just correspond with 
the health visitor and the GP in a non- urgent way be-
cause that is something that just needs to be added 
to their record but probably won’t impact on their 
health greatly. Site 2
The purpose of the CF NBS protocol in the UK is to 
maximise the detection of affected individuals (those with 
two disease causing mutations of the CF transmembrane 
regulator (CFTR) gene) while minimising the detection 
of unaffected carriers of CF. However, when carrier results 
are identified, these too need to be communicated to 
families. Similar to SCD, this occurs in a range of ways by 
different people, including general practitioners, health 
visitors, specialist nurses and genetic counsellors via tele-
phone or home visits.
CF carriers, we’ve got two specialist nurses within our 
screening lab and they actually go and do a home visit 
with the families and give them the CF carrier result 
in person Site 13
Feedback to the NBS laboratories regarding whether 
the parents had been informed of their baby’s SCD or CF 
carrier status and by whom was also of concern to some 
laboratories.
Resource use and responsibilities
NBS cards are used to collect blood from infants and 
information from their parents when the NBS heel prick 
sample is taken when the child is approximately 5 days 
of age. Procedures for processing NBS cards for the nine 
conditions currently included in the NBS Programme 
were considered to be transparent and efficient; clini-
cians within the NBS laboratories were able to discuss 
these in detail and seemed satisfied with how the labora-
tory guidelines were operationalised.
However, operationalising the communication aspect 
of the NBS pathways had clear implications in terms of 
resources; communicating positive newborn screening 
results for the screened conditions could be time 
consuming for a range of reasons. These included, not 
being able to contact the appropriate person or needing 
to wait for the appropriate busy clinician to return a tele-
phone call.
Sometimes…you’d speak to a secretary and you’d be 
waiting for a doctor to get back to you. So, it can take 
a few hours from when you’d started to try and pro-
cess that, depending on how quickly get back to you. 
Site 12
…it does sometimes feel like a bit of a battle trying to 
get hold of someone. Site 3
Again, this was also seen as being condition specific.
Once I know about a positive result (for CF or one of 
the metabolic conditions), ten, fifteen minutes….for 
CHT, I might be chasing around for an hour. Site 10
Due to the time- consuming nature of referring positive 
NBS results to the relevant professional or team, specialist 
screening professionals were highly valued by laboratory 
staff due to their knowledge of the conditions but also 
their ability to provide a link between the laboratory and 
the clinical teams. However, this service was not univer-
sally available.
We don’t have anything luxurious like a screening 
specialist nurse or anything like that, which I think 
probably would be extremely useful, but we don’t. 
Site 2
Once the screening result has been received by the rele-
vant member of the clinical team, a large amount of time 
is dedicated to organising and preparing for the family 
to be seen by the clinical team for the first time. The 
responsibility for this is shared and might be undertaken 
by the laboratory team, the consultant’s secretary and/or 
the consultant or clinical nurse specialist for the specific 
condition. This was often centre- specific and depends on 
local arrangements and resources.
Although quite unusual, in some areas, the NBS labo-
ratory would be responsible for arranging the appoint-
ment and sometimes the diagnostic tests. In others, this 
would be the responsibility of the specialist screening 
coordinator, screening nurse or screening health visitor. 
In other centres, this would be the responsibility of 
members of the relevant clinical team such as the consul-
tant or specialist nurse or midwife.
Communication pathways
Communication pathways for the 13 newborn screening 
laboratories in England for positive NBS results were 
developed from the interview responses. These described 
how positive NBS results were communicated from the 
NBS laboratory to parents via the clinical team and high-
lighted when variations occurred (online supplemental 
file 1).
DISCUSSION
The findings of this study indicate that NBS laboratory 
staff are acutely aware of the significance of a positive 
NBS result and the potential impact this could have on 
the family, even though in the majority of cases, they do 
not have direct contact with the family. Despite this, some 
challenges existed when communicating results from 
laboratories to relevant clinicians. These could involve 
time- consuming processes being employed to ensure 
the NBS ‘communication loop’ from the laboratory 
to clinical teams to families and back to the laboratory 
was closed. Nevertheless, laboratory staff in the present 
study were willing to invest the additional time and effort 
needed to ensure the performance thresholds of the NBS 
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Programme were met in particular in relation to referral 
of screen positive samples, and timely entry into clinical 
care for all screen positive babies referred to specialist 
services.25
The communication pathway for positive NBS results 
starts in the laboratory via relevant clinical teams and 
ends with the family of the affected child. Many studies 
have explored communication of positive NBS results to 
families11–16 but none have explored communication of 
NBS results between the laboratory and clinical teams 
involved in this process.
Although templates for the communication of posi-
tive NBS results exist, most laboratories had developed 
their own proformas, designed to meet local needs more 
explicitly. Although many laboratories stated these were 
based on the standard national templates, these had been 
adapted for a variety of reasons including: attempting to 
make the formatting of the proforma compatible with 
existing computer systems and data generated during 
processing of the NBS result; feedback from clinical 
teams regarding the content of information that would 
be useful when receiving the NBS result; and the addi-
tion of information to assist laboratories to obtain infor-
mation from clinical teams about when the baby had 
been seen so this information could be uploaded to the 
Child Health Information Service (CHIS) (clinical care 
records for children which contains information about 
a child’s public health interventions, such as screening, 
immunisations and outcomes). However, this meant that 
for clinical teams who received positive NBS results from 
more than one laboratory, the information and format 
used varied. It is known that variations exist both nation-
ally and internationally in terms of the approaches used 
to communicate positive NBS results to families11–16 but 
this would also seem to extend to the approaches used 
to communicate positive NBS results between clinicians. 
In addition, laboratory staff could spend considerable 
time trying to locate and make a referral to the correct 
clinician. Finally, obtaining the necessary feedback from 
clinical teams to enable the laboratories to complete 
their reporting processes could also be time- consuming 
and challenging. Although this is unlikely to influence 
communication with the family, it is important to ensure 
information relating to every child’s NBS journey is docu-
mented in a timely fashion and is available to relevant 
professionals involved in the child’s care. Interestingly, 
providing this feedback was not seen as being an issue by 
clinical staff, which suggests that they may not be aware of 
the information that is needed and could explain why in 
some cases this is not fed back in a timely manner.
The communication pathways identified some key 
similarities and differences between the different NBS 
laboratories. Key similarities included: contacting 
the relevant clinical team via telephone or in person 
(depending on physical proximity to the NBS labora-
tory) to alert them of a potential positive NBS positive 
result prior to sending the formal proforma, normally 
via secure email; requesting feedback from clinical teams 
regarding when the baby had been seen and the outcome 
(although this could either be in the form of a locally 
generated feedback form or a request for a copy of the 
clinic letter generated after the initial consultation with 
the child and family); and automatic upload of screening 
outcomes to the CHIS. Differences included: who in the 
clinical team was contacted by the NBS laboratory. This 
included the Consultant, Registrar, the Clinical Nurse 
Specialist, Specialist Health Visitors/Midwives, Genetic 
Counsellors and Screening/Pathway Co- ordinators. In 
some instances, this was condition specific but often this 
was determined by local arrangements and availability 
of resources. The person responsible for arranging the 
logistics of the initial appointment with the family also 
varied from the Consultant to more commonly the Clin-
ical Nurse Specialist to infrequently a member of labo-
ratory staff or the Consultant’s secretary. This variability 
reflects those observed when positive NBS results are 
communicated to families.11–16 Availability of specialist 
screening nurses who could act to bridge these processes 
by receiving the screening result, arrange the follow- up 
required and deliver the positive NBS result to the family, 
were highly valued by both laboratory staff and members 
of clinical teams and viewed as an example of good prac-
tice. Communication pathways for carrier results, the 
most common outcome for NBS screening particularly 
for SCD, also varied significantly by condition and locality.
Communicating positive NBS results for CHT seemed 
to be particularly problematic perhaps because commu-
nication is not always via a specialist clinical team due 
to CHT being viewed as manageable by general paedi-
atricians. Different models of care are in operation 
throughout the country and how these operate seemed 
to be influenced by local arrangements and resources but 
also to some extent historical influences. This often led 
to difficulties from the laboratory perspective: who the 
correct person was to refer a baby with suspected CHT 
to; a lack of confidence on occasions once the referral 
had been made; and concern that the child may not be 
followed up according to national guidelines. However, 
performance data from 2017 to 201826 27 indicates that 
92.7% of babies with a CHT positive screening result 
had a clinical referral initiated within 3 working days 
of sample receipt by the NBS laboratory, this compared 
with 100% of babies with MSUD, GA1, IVA, MCADD and 
99.1% of babies with PKU. In addition, 93% of children 
with CHT entered clinical care in a timely manner, this 
was higher than for those babies with MSUD (50.0%), 
PKU 61.1%), HCU (66.7%), CF (66.8%) and MCADD 
(76.2%). Therefore, while these performance data indi-
cate that difficulties communicating the positive NBS 
result for CHT may have hindered timely referral to rele-
vant clinical teams, this did not delay initiation of clinical 
care. Other conditions have dedicated clinical teams that 
focus solely on that condition (CF) or range of condi-
tions (SCD and the metabolic conditions) whereas babies 
with CHT are seen by endocrine teams who manage a 
range of other unrelated conditions in addition to CHT. 
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As such. the performance data26 27 indicates that referrals 
for these conditions were made more quickly although 
this was not reflected in the time taken to enter clin-
ical care. However, this could also reflect the differing 
complexities of these conditions in terms of treatment. 
Another factor that was considered to improve the 
referral process, particularly for the IMDs, was the close 
working relationships both physically and personally 
between laboratory staff and clinical teams were seen to 
enhance the referral process. However, this could also 
pose a potential risk if, for instance, relationships dete-
riorate or people move jobs. This was not evident in the 
present study but is perhaps something that needs careful 
consideration to avoid an over- reliance on relationships 
rather than robust systems.
Strengths and limitations
The current study has numerous strengths. This is the first 
known study that has explored communication pathways 
for positive NBS results from the laboratory to clinical 
teams. Participants represented the 13 NBS laboratories 
in England involved in managing the nine conditions 
currently included in the NBS programme, increasing 
the transferability of the findings. In addition, the study 
design, data collection and analysis were influenced by 
members of the PPI advisory group and relevant chari-
ties. In terms of limitations, the duration of the interviews 
ranged quite widely and the richness of the data collected 
was limited in the shorter interviews; in most instances, 
this was considered to reflect the limited experiences of 
some of the staff who were interviewed. The researchers 
are experienced in this field which may have biassed data 
collection and analysis.
Recommendations for practice
The findings of this study suggest a range of recom-
mended routes, with some key requirements for commu-
nication of positive NBS results from laboratories to 
clinicians, allowing for local variation and complexity, 
would be beneficial. This would ensure information 
sharing among the range of professionals involved 
nationally is optimised following a positive NBS result. 
This would include information required by laboratories 
to complete their processes, which would reduce demand 
on resources currently used to ensure this information is 
collected. Further research is needed to explore commu-
nication pathways for positive NBS results for CHT to 
ensure the process is streamlined and clear communica-
tion pathways are in place. While it is acknowledged that 
a single approach for processing CHT results may not 
be appropriate or necessary, transparency and complete 
information such as named contact individuals may help 
to ensure the process is less labour intensive, particularly 
from a laboratory perspective. In addition, to reduce 
variability in communication practices, the inclusion of 
specialist screening nurses as part of the NBS laboratory 
team was viewed as an example of good practice.
CONCLUSION
The importance of ensuring timely and effective commu-
nication of positive NBS results from laboratories to 
families via relevant clinicians was seen as a priority for 
all involved. Variation exists in terms of proformas and 
processes used to report positive NBS results to clinical 
teams, the approaches used and the people involved. 
This was often determined by local arrangements and 
resources. These different approaches could be time- 
consuming and challenging. Despite these challenges, 
ensuring quality and consistency was a clear priority for 
all NBS laboratories.
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